{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:50:24Z","timestamp":1787028624443,"version":"build-2736575974"},"reference-count":42,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>(1) Background: Alpha-synuclein (\u03b1-syn) is a presynaptic neuronal protein that regulates several neuronal functions. In recent decades, the role of \u03b1-syn as a biomarker of neurodegenerative diseases has been explored, especially in synucleinopathies. However, only a few studies have assessed its role as biomarker in other neurological disorders. The aim of the study was to evaluate cerebrospinal fluid (CSF) \u03b1-syn levels in several neurological disorders; (2) Methods: We measured CSF \u03b1-syn levels by a commercial ELISA kit in 158 patients classified in the following group: controls, Alzheimer\u2019s Disease (AD), cerebrovascular diseases, inflammatory central nervous system diseases, other neurological diseases, Parkinson\u2019s Disease (PD), and peripheral neuropathy; (3) Results: Patients with PD showed the lowest and patients with AD the highest levels of CSF \u03b1-syn (1372 vs. 2912 pg\/mL, respectively, p &lt; 0.001). In AD patients, \u03b1-syn levels were significantly associated with tau proteins; (4) Conclusions: \u03b1-syn could represent a biomarker of neurodegenerative diseases.<\/jats:p>","DOI":"10.3390\/jcm11113139","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T03:33:18Z","timestamp":1654054398000},"page":"3139","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders"],"prefix":"10.3390","volume":"11","author":[{"given":"Luisa","family":"Agnello","sequence":"first","affiliation":[{"name":"Institute of Clinical Biochemistry, Clinical Molecular Medicine and Clinical Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Lo Sasso","sequence":"additional","affiliation":[{"name":"Institute of Clinical Biochemistry, Clinical Molecular Medicine and Clinical Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy"},{"name":"Department of Laboratory Medicine, Azienda Ospedaliera Universitaria Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9991-7502","authenticated-orcid":false,"given":"Matteo","family":"Vidali","sequence":"additional","affiliation":[{"name":"Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Scazzone","sequence":"additional","affiliation":[{"name":"Institute of Clinical Biochemistry, Clinical Molecular Medicine and Clinical Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina Maria","family":"Gambino","sequence":"additional","affiliation":[{"name":"Institute of Clinical Biochemistry, Clinical Molecular Medicine and Clinical Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy"},{"name":"Department of Laboratory Medicine, Azienda Ospedaliera Universitaria Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3410-2067","authenticated-orcid":false,"given":"Tommaso","family":"Piccoli","sequence":"additional","affiliation":[{"name":"Unit of Neurology, Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1723-3305","authenticated-orcid":false,"given":"Giulia","family":"Bivona","sequence":"additional","affiliation":[{"name":"Institute of Clinical Biochemistry, Clinical Molecular Medicine and Clinical Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Ciaccio","sequence":"additional","affiliation":[{"name":"Unit of Clinical Biochemistry, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria Vincenza","family":"Giglio","sequence":"additional","affiliation":[{"name":"Institute of Clinical Biochemistry, Clinical Molecular Medicine and Clinical Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy"},{"name":"Department of Laboratory Medicine, Azienda Ospedaliera Universitaria Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2045-1864","authenticated-orcid":false,"given":"Vincenzo","family":"La Bella","sequence":"additional","affiliation":[{"name":"ALS Clinical Research Center and Laboratory of Neurochemistry, Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6120-9041","authenticated-orcid":false,"given":"Marcello","family":"Ciaccio","sequence":"additional","affiliation":[{"name":"Institute of Clinical Biochemistry, Clinical Molecular Medicine and Clinical Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy"},{"name":"Department of Laboratory Medicine, Azienda Ospedaliera Universitaria Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0166-2236(97)01213-7","article-title":"The synucleins: A family of proteins involved in synaptic function, plasticity, neurodegeneration and disease","volume":"21","author":"Clayton","year":"1998","journal-title":"Trends Neurosci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nan.12298","article-title":"Review: Sporadic Parkinson\u2019s disease: Development and distribution of \u03b1-synuclein pathology","volume":"42","author":"Braak","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_3","first-page":"699","article-title":"The Synaptic Function of \u03b1-Synuclein","volume":"5","year":"2015","journal-title":"J. Park. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1073\/pnas.1913904117","article-title":"The process of Lewy body formation, rather than simply \u03b1-synuclein fibrillization, is one of the major drivers of neurodegeneration","volume":"117","author":"Burtscher","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/jnc.12131","article-title":"Activity-dependent secretion of alpha-synuclein by enteric neurons","volume":"125","author":"Paillusson","year":"2013","journal-title":"J. Neurochem."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Emmanouilidou, E., Elenis, D., Papasilekas, T., Stranjalis, G., Gerozissis, K., Ioannou, P.C., and Vekrellis, K. (2011). Assessment of \u03b1-synuclein secretion in mouse and human brain parenchyma. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0022225"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","article-title":"\u03b1-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: A cohort study","volume":"10","author":"Mollenhauer","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_8","first-page":"1945","article-title":"Alpha-synuclein implicated in Parkinson\u2019s disease is present in extracellular biological fluids, including human plasma","volume":"17","author":"Salem","year":"2003","journal-title":"FASEB J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/mds.27110","article-title":"Diagnostic utility of cerebrospinal fluid \u03b1-synuclein in Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"32","author":"Eusebi","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","article-title":"CSF and blood biomarkers for Parkinson\u2019s disease","volume":"18","author":"Parnetti","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Constantinides, V.C., Majbour, N.K., Paraskevas, G.P., Abdi, I., Safieh-Garabedian, B., Stefanis, L., El-Agnaf, O.M., and Kapaki, E. (2021). Cerebrospinal Fluid \u03b1-Synuclein Species in Cognitive and Movements Disorders. Brain Sci., 11.","DOI":"10.3390\/brainsci11010119"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/labmed\/lmaa062","article-title":"Neurogranin as a Novel Biomarker in Alzheimer\u2019s Disease","volume":"52","author":"Agnello","year":"2021","journal-title":"Lab. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/ana.22311","article-title":"Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression","volume":"69","author":"Shi","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"121ra20","DOI":"10.1126\/scitranslmed.3002566","article-title":"Phosphorylated \u03b1-synuclein in Parkinson\u2019s disease","volume":"4","author":"Wang","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_15","first-page":"107","article-title":"Neuropathological and Biomarker Findings in Parkinson\u2019s Disease and Alzheimer\u2019s Disease: From Protein Aggregates to Synaptic Dysfunction","volume":"11","author":"Compta","year":"2021","journal-title":"J. Park. Dis."},{"key":"ref_16","first-page":"e12177","article-title":"Interaction of CSF \u03b1-synuclein and amyloid beta in cognition and cortical atrophy","volume":"13","author":"Lee","year":"2021","journal-title":"Alzheimer\u2019s Dement. Diagn. Assess. Dis. Monit."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3233\/JAD-141287","article-title":"Cerebrospinal fluid \u03b1-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer\u2019s disease","volume":"43","author":"Mackin","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40035-019-0172-x","article-title":"Beyond the synucleinopathies: Alpha synuclein as a driving force in neurodegenerative comorbidities","volume":"8","author":"Visanji","year":"2019","journal-title":"Transl. Neurodegener."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5483\/BMBRep.2017.50.5.038","article-title":"Synapses in neurodegenerative diseases","volume":"50","author":"Bae","year":"2017","journal-title":"BMB Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2217\/bmm.12.46","article-title":"Recommendations to standardize preanalytical confounding factors in Alzheimer\u2019s and Parkinson\u2019s disease cerebrospinal fluid biomarkers: An update","volume":"6","author":"Mollenhauer","year":"2012","journal-title":"Biomark. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1590\/1980-57642020dn14-030005","article-title":"Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing \u201cwhere\u201d by \u201cwhat\u201d\u2026","volume":"14","author":"Allegri","year":"2020","journal-title":"Dement. Neuropsychol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1177271920950319","DOI":"10.1177\/1177271920950319","article-title":"Fluid Biomarkers for Synaptic Dysfunction and Loss","volume":"15","author":"Camporesi","year":"2020","journal-title":"Biomark. Insights"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/ene.14789","article-title":"Tau protein as a diagnostic and prognostic biomarker in amyotrophic lateral sclerosis","volume":"28","author":"Agnello","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Colletti, T., Agnello, L., Spataro, R., Guccione, L., Notaro, A., Lo Sasso, B., Blandino, V., Graziano, F., Gambino, C.M., and Giglio, R.V. (2021). Prognostic Role of CSF \u03b2-amyloid 1-42\/1-40 Ratio in Patients Affected by Amyotrophic Lateral Sclerosis. Brain Sci., 11.","DOI":"10.3390\/brainsci11030302"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer\u2019s disease: The IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/00365513.2020.1740939","article-title":"Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis","volume":"80","author":"Agnello","year":"2020","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"McGrowder, D.A., Miller, F., Vaz, K., Nwokocha, C., Wilson-Clarke, C., Anderson-Cross, M., Brown, J., Anderson-Jackson, L., Williams, L., and Latore, L. (2021). Cerebrospinal Fluid Biomarkers of Alzheimer\u2019s Disease: Current Evidence and Future Perspectives. Brain Sci., 11.","DOI":"10.3390\/brainsci11020215"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-019-0320-x","article-title":"\u03b1-synuclein in the pathophysiology of Alzheimer\u2019s disease","volume":"14","author":"Twohig","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/mds.26036","article-title":"Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: Evidence from a meta-analysis","volume":"29","author":"Sako","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_31","first-page":"567386","article-title":"The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid \u03b1 -Synuclein Levels in Parkinson\u2019s Disease: A Meta-Analysis","volume":"2015","author":"Zhou","year":"2015","journal-title":"Park. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3109\/00207454.2014.961454","article-title":"Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson\u2019s disease diagnosis: A systematic review and meta-analysis","volume":"125","author":"Gao","year":"2015","journal-title":"Int. J. Neurosci."},{"key":"ref_33","first-page":"132","article-title":"Assessment of cerebrospinal fluid \u03b1-synuclein as a potential biomarker in Parkinson\u2019s disease and synucleinopathies","volume":"7","author":"Chalatsa","year":"2020","journal-title":"Neuroimmunol. Neuroinflamm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1017\/S1041610215000447","article-title":"Use of CSF \u03b1-synuclein in the differential diagnosis between Alzheimer\u2019s disease and other neurodegenerative disorders","volume":"27","author":"Wang","year":"2015","journal-title":"Int. Psychogeriatr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13195-017-0276-4","article-title":"Differential role of CSF fatty acid binding protein 3, \u03b1-synuclein, and Alzheimer\u2019s disease core biomarkers in Lewy body disorders and Alzheimer\u2019s dementia","volume":"9","author":"Chiasserini","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"40263","DOI":"10.1038\/srep40263","article-title":"Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer\u2019s disease","volume":"7","author":"Majbour","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Vacchi, E., Kaelin-Lang, A., and Melli, G. (2020). Tau and Alpha Synuclein Synergistic Effect in Neurodegenerative Diseases: When the Periphery Is the Core. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21145030"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1100\/2011\/371893","article-title":"Interaction between \u03b1-synuclein and other proteins in neurodegenerative disorders","volume":"11","author":"Jellinger","year":"2011","journal-title":"Sci. World J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"10253","DOI":"10.1523\/JNEUROSCI.0581-12.2012","article-title":"Soluble \u03b1-synuclein is a novel modulator of Alzheimer\u2019s disease pathophysiology","volume":"32","author":"Larson","year":"2012","journal-title":"J. Neurosci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","article-title":"Synergistic Interactions between Abeta, tau, and alpha-synuclein: Acceleration of neuropathology and cognitive decline","volume":"30","author":"Clinton","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/jnc.14569","article-title":"Antibody-based methods for the measurement of \u03b1-synuclein concentration in human cerebrospinal fluid-method comparison and round robin study","volume":"149","author":"Mollenhauer","year":"2019","journal-title":"J. Neurochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.seizure.2015.02.007","article-title":"Alpha-synuclein is a potential biomarker in the serum and CSF of patients with intractable epilepsy","volume":"27","author":"Rong","year":"2015","journal-title":"Seizure"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/11\/3139\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:22:53Z","timestamp":1760138573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/11\/3139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["jcm11113139"],"URL":"https:\/\/doi.org\/10.3390\/jcm11113139","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]}}}